EE53 Cost-Minimization and Budget Impact Analysis of Venetoclax Versus Acalabrutinib for 1L and R/R Chronic Lymphocytic Leukemia in the Brazilian Public Healthcare System
Jun 1, 2023, 00:00 AM
10.1016/j.jval.2023.03.358
https://www.valueinhealthjournal.com/article/S1098-3015(23)00458-8/fulltext
Section Title :
Section Order :
11745
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00458-8&doi=10.1016/j.jval.2023.03.358